Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Ever Supreme Bio Technology Co EV-to-EBITDA?
Ever Supreme Bio Technology CoROCO:6712 92 EV-to-EBITDA is 24.27 as of Sep. 14, 2026, which is 3% above its 10-year median of 23.54. GuruFocus rates ROCO:6712 with a GF Score™ of 92/100 and a GF Value™ of NT$179.82 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 404 Biotechnology companies, Ever Supreme Bio Technology Co ranks worse than 66.58% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ever Supreme Bio Technology Co's enterprise value is NT$14,651 Mil.
Ever Supreme Bio Technology Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$604 Mil. Therefore, Ever Supreme Bio Technology Co's EV-to-EBITDA for today is 24.27.
The historical rank and industry rank for Ever Supreme Bio Technology Co's EV-to-EBITDA or its related term are showing as below:
ROCO:6712'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -474.94 Med: 23.54 Max: 652.42
Current: 24.27
During the past 10 years, the highest EV-to-EBITDA of Ever Supreme Bio Technology Co was 652.42. The lowest was -474.94. And the median was 23.54.
ROCO:6712's EV-to-EBITDA is ranked worse than 66.58% of 404
companies
in the Biotechnology industry
Industry Median: 13.02
vs ROCO:6712: 24.27
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Ever Supreme Bio Technology Co (ROCO:6712) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ever Supreme Bio Technology Co's PE Ratio (TTM) for today is calculated as:
Ever Supreme Bio Technology Co's share price for today is NT$154.00.
Ever Supreme Bio Technology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$4.938.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6712 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Ever Supreme Bio Technology Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ever Supreme Bio Technology Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ever Supreme Bio Technology Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ever Supreme Bio Technology Co's EV-to-EBITDA falls into.
Ever Supreme Bio Technology Co's current Enterprise Value is NT$14,651 Mil.
Ever Supreme Bio Technology Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$604 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ever Supreme Bio Technology Co (ROCO:6712) has a EV-to-EBITDA of 24.27 as of Sep. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ever Supreme Bio Technology Co. This is near median its historical median of 23.54. According to the industry distribution chart, Ever Supreme Bio Technology Co ranks #269 out of 404 companies in the Biotechnology industry, placing it in the top 66.6%.
Is Ever Supreme Bio Technology Co's EV-to-EBITDA too high?
Ever Supreme Bio Technology Co's current EV-to-EBITDA of 24.27 is near median its 10-year median of 23.54. The Biotechnology industry median EV-to-EBITDA is 13.02. Ever Supreme Bio Technology Co's value of 24.27 is 86.4% above this industry median. Based on the distribution chart, Ever Supreme Bio Technology Co ranks #269 out of 404 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ever Supreme Bio Technology Co has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ever Supreme Bio Technology Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ever Supreme Bio Technology Co ranks #269 out of 404 companies for EV-to-EBITDA. This places Ever Supreme Bio Technology Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.02. Ever Supreme Bio Technology Co's value of 24.27 is 86.4% above this benchmark. While the company's 10-year median is 23.54 vs. the industry median of 13.02, Ever Supreme Bio Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.02, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ever Supreme Bio Technology Co's current EV-to-EBITDA of 24.27 is 86.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ever Supreme Bio Technology Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ever Supreme Bio Technology Co's current EV-to-EBITDA is 24.27, which is near median its own 10-year median of 23.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ever Supreme Bio Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Ever Supreme Bio Technology Co (ROCO:6712) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$179.82, compared to a current price of NT$154.00 — trading 14.4% below its estimated fair value. The current EV-to-EBITDA is 24.27, which is near median its 10-year median of 23.54 and 86.4% above the Biotechnology industry median of 13.02. Ever Supreme Bio Technology Co's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Ever Supreme Bio Technology Co (ROCO:6712), the current EV-to-EBITDA is 24.27 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ever Supreme Bio Technology Co (ROCO:6712) Overvalued in 2026?
Based on GuruFocus' analysis, Ever Supreme Bio Technology Co stock appears to be undervalued.
The current stock price of NT$154.00 is trading 14.4% below its estimated GF Value™ of NT$179.82.
GuruFocus considers Ever Supreme Bio Technology Co to be Modestly Undervalued.
Key valuation signals for ROCO:6712:
EV-to-EBITDA: 24.27 (near median its 10-year median of 23.54)
GF Value™: NT$179.82 vs. price of NT$154.00 (14.4% below fair value)
Industry Position: 86.4% above the Biotechnology median (#269 of 404)
No single metric tells the full story. See the ROCO:6712 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ever Supreme Bio Technology Co Ltd is a Taiwan-based company. The company is engaged in research, development, and manufacturing of new drugs related to human mesenchymal stem cells and immune cells. The company operates in two segments: Cell Preparation Business Unit and Other Operating Business. The company gained a majority of revenue from the Cell Preparation Business, which is engaged in the research, development, manufacture, and sales of various new drugs and cell preparations, and investments related to biotechnology and medical industry businesses.
92GF Score
Get the complete analysis for ROCO:6712
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6712 has been successfully added to your 
